Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Researchers evaluated billing for early palliative care among Medicare beneficiaries who were newly diagnosed with 1 of 6 common distant-stage cancers.

NIH officials have urged scientists to remove all references to mRNA vaccine technology from their grant applications.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Two Harvard medical school professors are suing the Trump administration, arguing that their research was unfairly removed from a government-run website.

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.